ReviewMolecular medicine reports2026
Mechanistic insights and therapeutic potential of sphingosine‑1‑phosphate in the development of pulmonary fibrosis (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S1P, Generated by Sphingosine Kinase 1, Negatively Affects Corneal Wound Healing Process by Activating TGF-β/Smad Pathway.Analytical cellular pathology (Amsterdam) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis represents a group of chronic, progressive lung disorders arising from diverse etiological factors. Its defining pathological feature is the excessive deposition of collagen, which ultimately results in irreversible distortion of the lung parenchyma. Current therapeutic strategies can slow disease progression but are insufficient to halt it completely. Sphingosine‑1‑phosphate (S1P) is a bioactive sphingolipid metabolite that binds to sphingosine‑1‑phosphate receptors (S1PRs) to regulate numerous vital intracellular metabolic pathways associated with cell proliferation, survival and apoptosis. The present reviewsummarizedthe molecular network through which S1P contributes to the pathogenesis of pulmonary fibrosis, outlines existing pharmacological modulators of the S1P pathway anddiscussedtheir potential therapeutic value in treating this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.